FDCBSEFDC LIMITEDMediumPositive
Announced Thu, 13 Aug · 14:23 IST

FDC subsidiary gets UK MHRA approval for Atropine eye drops

Regulatory Product ApprovalBusiness Updates View source PDFExplain this filing

FDC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.3%1-day move
₹354.70
prior close
₹358.35
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4-0.2-0.2+0.4+0.3-0.2-0.9-2.5-1.1
Up moveDown movePending
AI summary

FDC Limited's subsidiary FDC International Limited has received Marketing Authorisation from the UK's MHRA for Atropine 1.0 percent w/v Eye Drops Solution. MHRA approval allows the subsidiary to market and sell this ophthalmic product in the United Kingdom, giving FDC a regulatory pathway into the UK pharmaceutical market for Atropine eye drops.

Likely market impact

Positive. UK clearance lets FDC subsidiary commercialise Atropine eye drops in Britain, supporting future export revenue from a hard-currency market.